Our study also suggested that concurrent inhibition of PI3Kα and RAS/MEK is worthwhile to be considered in the treatment of ESCC harboring mutation in KRAS or HRAS. The gene discussed is MAP2K7; the disease is esophageal squamous cell carcinoma.